The company’s 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred during 2026, as both cannot be reliably forecasted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, February 04, 2026
- Is AbbVie Stock (ABBV) a Good Buy ahead of Q4 Earnings?
- These Are the Stocks Reporting Earnings Today – February 4, 2026
- Notable companies reporting before tomorrow’s open
- AbbVie submits regulatory applications to FDA and EMA for upadacitinib in vitigo